VERAXA Biotech (NASDAQ: VRXA) is spotlighting its proprietary BiTAC-ADC and BiTAC-TCE technology platforms at the BIO International Convention, which runs from June 22 to June 25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, designed to enhance cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
According to VERAXA, these findings, along with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the convention. The full press release is available at https://ibn.fm/r8zEz.
VERAXA Biotech AG is building a premier engine for discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to the company as of the date hereof. The company undertakes no duty to update this information unless required by law.
